242 related articles for article (PubMed ID: 27957732)
1. Chronic vulvovaginal candidiasis in patients using a levonorgestrel-containing intrauterine device.
Nguyen Y; Fischer G
Australas J Dermatol; 2018 Feb; 59(1):e39-e42. PubMed ID: 27957732
[TBL] [Abstract][Full Text] [Related]
2. Management of chronic vulvovaginal candidiasis: a long term retrospective study.
Nguyen Y; Lee A; Fischer G
Australas J Dermatol; 2017 Nov; 58(4):e188-e192. PubMed ID: 27250078
[TBL] [Abstract][Full Text] [Related]
3. [Application of levonorgestrel-releasing intrauterine system in early pregnancy: a case report].
Gardyszewska A; Czajkowski K
Ginekol Pol; 2012 Dec; 83(12):950-2. PubMed ID: 23488301
[TBL] [Abstract][Full Text] [Related]
4. Endothelial function in women using levonorgestrel-releasing intrauterine system (LNG-IUS).
Selim MF; Hussein AF
Contraception; 2013 Apr; 87(4):396-403. PubMed ID: 23332246
[TBL] [Abstract][Full Text] [Related]
5. Body weight and composition in users of levonorgestrel-releasing intrauterine system.
Dal'Ava N; Bahamondes L; Bahamondes MV; de Oliveira Santos A; Monteiro I
Contraception; 2012 Oct; 86(4):350-3. PubMed ID: 22445431
[TBL] [Abstract][Full Text] [Related]
6. Vaginal flora changes on Pap smears after insertion of levonorgestrel-releasing intrauterine device.
Donders GG; Berger J; Heuninckx H; Bellen G; Cornelis A
Contraception; 2011 Apr; 83(4):352-6. PubMed ID: 21397094
[TBL] [Abstract][Full Text] [Related]
7. Comparative contraceptive effectiveness of levonorgestrel-releasing and copper intrauterine devices: the European Active Surveillance Study for Intrauterine Devices.
Heinemann K; Reed S; Moehner S; Minh TD
Contraception; 2015 Apr; 91(4):280-3. PubMed ID: 25601350
[TBL] [Abstract][Full Text] [Related]
8. Levonorgestrel-releasing intrauterine system (LNG-IUS 12) for prevention of pregnancy for up to five years.
Nelson AL
Expert Rev Clin Pharmacol; 2017 Aug; 10(8):833-842. PubMed ID: 28617060
[TBL] [Abstract][Full Text] [Related]
9. Comparison of copper intrauterine device with levonorgestrel-bearing intrauterine system for post-abortion contraception.
Bilgehan F; Dilbaz B; Karadag B; Deveci CD
J Obstet Gynaecol Res; 2015 Sep; 41(9):1426-32. PubMed ID: 26180028
[TBL] [Abstract][Full Text] [Related]
10. A multicentre, open-label, randomised phase III study comparing a new levonorgestrel intrauterine contraceptive system (LNG-IUS 8) with combined oral contraception in young women of reproductive age.
Borgatta L; Buhling KJ; Rybowski S; Roth K; Rosen K
Eur J Contracept Reprod Health Care; 2016 Oct; 21(5):372-9. PubMed ID: 27494570
[TBL] [Abstract][Full Text] [Related]
11. Quantitative levonorgestrel plasma level measurements in patients with regular and prolonged use of the levonorgestrel-releasing intrauterine system.
Seeber B; Ziehr SC; Gschlieβer A; Moser C; Mattle V; Seger C; Griesmacher A; Concin N; Concin H; Wildt L
Contraception; 2012 Oct; 86(4):345-9. PubMed ID: 22402256
[TBL] [Abstract][Full Text] [Related]
12. Selection and performance of the levonorgestrel-releasing intrauterine system.
Lähteenmäki P; Bardin CW; Elomaa K; Haukkamaa M; Kivijärvi A; Kuukankorpi A; Venhola M; Tuominen J
Acta Obstet Gynecol Scand Suppl; 1997; 164():69-74. PubMed ID: 9225643
[TBL] [Abstract][Full Text] [Related]
13. Complication rates associated with levonorgestrel intrauterine system use in adolescents with developmental disabilities.
Savasi I; Jayasinghe K; Moore P; Jayasinghe Y; Grover SR
J Pediatr Adolesc Gynecol; 2014 Feb; 27(1):25-8. PubMed ID: 24315712
[TBL] [Abstract][Full Text] [Related]
14. Levonorgestrel-Releasing Intrauterine System for Women With Polycystic Ovary Syndrome: Metabolic and Clinical Effects.
da Silva AV; de Melo AS; Barboza RP; de Paula Martins W; Ferriani RA; Vieira CS
Reprod Sci; 2016 Jul; 23(7):877-84. PubMed ID: 26733500
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two cohorts of women who expulsed either a copper-intrauterine device or a levonorgestrel-releasing intrauterine system.
Simonatto P; Bahamondes MV; Fernandes A; Silveira C; Bahamondes L
J Obstet Gynaecol Res; 2016 May; 42(5):554-9. PubMed ID: 26817571
[TBL] [Abstract][Full Text] [Related]
16. A Phase III, single-arm study of LNG-IUS 8, a low-dose levonorgestrel intrauterine contraceptive system (total content 13.5mg) in postmenarcheal adolescents.
Gemzell-Danielsson K; Buhling KJ; Dermout SM; Lukkari-Lax E; Montegriffo E; Apter D
Contraception; 2016 Jun; 93(6):507-12. PubMed ID: 26872720
[TBL] [Abstract][Full Text] [Related]
17. Weight variation in users of depot-medroxyprogesterone acetate, the levonorgestrel-releasing intrauterine system and a copper intrauterine device for up to ten years of use.
Modesto W; de Nazaré Silva dos Santos P; Correia VM; Borges L; Bahamondes L
Eur J Contracept Reprod Health Care; 2015 Feb; 20(1):57-63. PubMed ID: 25160484
[TBL] [Abstract][Full Text] [Related]
18. Effects of levonorgestrel-releasing intrauterine system and T380A intrauterine copper device on dysmenorrhea and days of bleeding in women with and without adenomyosis.
Kelekci S; Kelekci KH; Yilmaz B
Contraception; 2012 Nov; 86(5):458-63. PubMed ID: 22832203
[TBL] [Abstract][Full Text] [Related]
19. The levonorgestrel intrauterine system: cohort study to assess satisfaction in a postpartum population in Kenya.
Hubacher D; Masaba R; Manduku CK; Chen M; Veena V
Contraception; 2015 Apr; 91(4):295-300. PubMed ID: 25601351
[TBL] [Abstract][Full Text] [Related]
20. Pain and bleeding pattern related to levonorgestrel intrauterine system (LNG-IUS) insertion.
Van Schoubroeck D; Van den Bosch T; Ameye L; Veldman J; Hindryckx A; Werbrouck E; Timmerman D
Eur J Obstet Gynecol Reprod Biol; 2013 Nov; 171(1):154-6. PubMed ID: 24029596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
